^“Pluripotency redux--advances in stem-cell research”. The New England Journal of Medicine357 (15): 1469–72. (October 2007). doi:10.1056/NEJMp078126. PMID17928593.
^“Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc”. Oncogene6 (8): 1453–7. (August 1991). PMID1886715.
^“Cell-cycle control of c-myc but not c-ras expression is lost following chemical transformation”. Cell36 (2): 241–7. (1984). doi:10.1016/0092-8674(84)90217-4. PMID6692471.
^“Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies”. Gynecologic Oncology130 (3): 554–9. (September 2013). doi:10.1016/j.ygyno.2013.06.019. PMID23791828.
^“Tumor induction by ras and myc oncogenes in fetal and neonatal brain: modulating effects of developmental stage and retroviral dose”. Acta Neuropathologica86 (5): 456–65. (1993). doi:10.1007/bf00228580. PMID8310796.
^ ab“A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer”. The Journal of Biological Chemistry277 (23): 20965–73. (June 2002). doi:10.1074/jbc.M112231200. PMID11916966.
^“Inhibition of human telomerase reverse transcriptase gene expression by BRCA1 in human ovarian cancer cells”. Biochemical and Biophysical Research Communications303 (1): 130–6. (March 2003). doi:10.1016/s0006-291x(03)00318-8. PMID12646176.
^“BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells”. Oncogene17 (15): 1939–48. (October 1998). doi:10.1038/sj.onc.1202403. PMID9788437.
^ ab“Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation”. The Journal of Biological Chemistry279 (38): 40209–19. (September 2004). doi:10.1074/jbc.M404056200. PMID15210690.
^“c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis”. Oncogene22 (36): 5707–11. (August 2003). doi:10.1038/sj.onc.1206800. PMID12944920.
^“BioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors”. Journal of Proteomics118 (12): 95–111. (April 2015). doi:10.1016/j.jprot.2014.09.029. PMID25452129.
^“CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells”. The Journal of Biological Chemistry280 (20): 20086–93. (May 2005). doi:10.1074/jbc.M410036200. PMID15769738.
^“Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase”. The Journal of Biological Chemistry274 (46): 32580–7. (November 1999). doi:10.1074/jbc.274.46.32580. PMID10551811.
^ ab“The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins”. Cell94 (3): 363–74. (August 1998). doi:10.1016/s0092-8674(00)81479-8. PMID9708738.
^ ab“c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function”. Nature Genetics22 (1): 102–5. (May 1999). doi:10.1038/8811. PMID10319872.
^ ab“Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX”. Oncogene22 (6): 819–25. (February 2003). doi:10.1038/sj.onc.1206252. PMID12584560.
^“Mlx, a novel Max-like BHLHZip protein that interacts with the Max network of transcription factors”. The Journal of Biological Chemistry274 (51): 36344–50. (December 1999). doi:10.1074/jbc.274.51.36344. PMID10593926.
^“Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc”. Oncogene16 (9): 1149–59. (March 1998). doi:10.1038/sj.onc.1201634. PMID9528857.
^“X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors”. Cell112 (2): 193–205. (January 2003). doi:10.1016/s0092-8674(02)01284-9. PMID12553908.
^“Differential effects of the widely expressed dMax splice variant of Max on E-box vs initiator element-mediated regulation by c-Myc”. Oncogene18 (15): 2489–98. (April 1999). doi:10.1038/sj.onc.1202611. PMID10229200.
^“Mlx, a new Max-like bHLHZip family member: the center stage of a novel transcription factors regulatory pathway?”. Oncogene19 (29): 3266–77. (July 2000). doi:10.1038/sj.onc.1203634. PMID10918583.
^“Mechanism for the transcriptional repression by c-Myc on PDGF beta-receptor”. Journal of Cell Science114 (Pt 8): 1533–44. (April 2001). PMID11282029.
^“Cell cycle-dependent switch of up-and down-regulation of human hsp70 gene expression by interaction between c-Myc and CBF/NF-Y”. The Journal of Biological Chemistry274 (34): 24270–9. (August 1999). doi:10.1074/jbc.274.34.24270. PMID10446203.
^“p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression”. The Journal of Biological Chemistry277 (35): 31694–702. (August 2002). doi:10.1074/jbc.M200266200. PMID12080043.
^“MM-1, a novel c-Myc-associating protein that represses transcriptional activity of c-Myc”. The Journal of Biological Chemistry273 (45): 29794–800. (November 1998). doi:10.1074/jbc.273.45.29794. PMID9792694.
^“MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer”. The Journal of Biological Chemistry276 (48): 45137–44. (November 2001). doi:10.1074/jbc.M106127200. PMID11567024.
^ ab“Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B)”. Molecular Cell9 (1): 133–43. (January 2002). doi:10.1016/s1097-2765(01)00430-0. PMID11804592.
^“Guanine nucleotide exchange factor, Tiam1, directly binds to c-Myc and interferes with c-Myc-mediated apoptosis in rat-1 fibroblasts”. The Journal of Biological Chemistry278 (7): 5132–40. (February 2003). doi:10.1074/jbc.M206733200. PMID12446731.
^“Repression of p15INK4b expression by Myc through association with Miz-1”. Nature Cell Biology3 (4): 392–9. (April 2001). doi:10.1038/35070076. PMID11283613.
“The proto-oncogene c-myc in hematopoietic development and leukemogenesis”. Oncogene21 (21): 3414–21. (May 2002). doi:10.1038/sj.onc.1205400. PMID12032779.
“c-MYC: more than just a matter of life and death”. Nature Reviews. Cancer2 (10): 764–76. (October 2002). doi:10.1038/nrc904. PMID12360279.
“Could MYC induction of mitochondrial biogenesis be linked to ROS production and genomic instability?”. Cell Cycle4 (11): 1465–6. (November 2005). doi:10.4161/cc.4.11.2121. PMID16205115.
“Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant”. Genes & Development6 (4): 642–54. (April 1992). doi:10.1101/gad.6.4.642. PMID1559612.
“DNA-activated protein kinase in Raji Burkitt's lymphoma cells. Phosphorylation of c-Myc oncoprotein”. European Journal of Biochemistry / FEBS206 (2): 595–603. (June 1992). doi:10.1111/j.1432-1033.1992.tb16964.x. PMID1597196.
“A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression”. The Journal of Biological Chemistry266 (35): 23521–4. (December 1991). PMID1748630.
“Mapping of the MYC gene to band 8q24.12----q24.13 by R-banding and distal to fra(8)(q24.11), FRA8E, by fluorescence in situ hybridization”. Cytogenetics and Cell Genetics57 (2–3): 109–11. (1991). doi:10.1159/000133124. PMID1914517.
“Nucleotide sequence 3' to the human c-myc oncogene; presence of a long inverted repeat”. Gene72 (1–2): 105–8. (December 1988). doi:10.1016/0378-1119(88)90131-X. PMID3243428.
“A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas”. Cell52 (2): 185–95. (January 1988). doi:10.1016/0092-8674(88)90507-7. PMID3277717.